Antiplatelet Properties of Oral Anticoagulants

Until recently, vitamin K antagonists (VKA) were the only oral anticoagulant drugs used in clinical practice for stroke or systemic embolism prevention in patients with non-valvular atrial fibrillation (AF). New oral anticoagulant drugs such as dabigatran etexilate and rivaroxaban have been developed and are currently available as an alternative in this indication. Both drugs were demonstrated to be non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with non-valvular AF in the RE-LY and ROCKET trials [1,2].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Letter to the Editor Source Type: research